Testing the Combination of the Anti-Cancer Drugs Temozolomide and M1774 to Evaluate Their Safety and Effectiveness

Recruiting

Phase 1

Phase 2

Testing the Combination of the Anti-Cancer Drugs Temozolomide and M1774 to Evaluate Their Safety and Effectiveness

Sponsor:

National Cancer Institute (NCI)

Code:

NCT05691491

Conditions

Advanced Malignant Solid Neoplasm

Advanced Microsatellite Stable Colorectal Carcinoma

Hematopoietic and Lymphatic System Neoplasm

Metastatic Malignant Solid Neoplasm

Metastatic Microsatellite Stable Colorectal Carcinoma

Eligibility Criteria

Sex: All

Age: 18+

Healthy Volunteers: Not accepted

Interventions

Biopsy Procedure

Biospecimen Collection

Computed Tomography

Magnetic Resonance Imaging

Temozolomide

Study Details

Eligibility Criteria

Study Design

Interventions and Outcome Measures

Central Contacts and Locations

More Information

Trial information was received from ClinicalTrials.gov and was last updated on 2025-07-12. This information was provided to ClinicalTrials.gov by National Cancer Institute (NCI) on 2025-04-09.